Figure 4.

Ki‐67 expression on CCR6+/−CD20⁺ B cells following KLH administration in animals treated with vehicle or i.v. 300 mg·kg⁻¹ VIB4920 in Study 2 (N = 12). VIB4920 treatment inhibits the B‐cell proliferative response following secondary KLH administration. (a) Flow cytometry plots are pre‐gated on CD20+ lymphocytes and show the percent CCR6+/⁻Ki‐67⁺ for six representative animals; the change over time in circulating (b) CCR6+ (c) CCR6− Ki‑67⁺ B‐cell count (as frequency of gated CD20⁺) in animals treated with vehicle, or i.v. 50, 150, or 300 mg·kg⁻¹ VIB4920. Proliferation is significantly affected on Days 15 and 29 of the dosing phase and on Day 43 of the recovery phase. *P ≤ .05, significantly different from vehicle group; one‐way ANOVA with Dunnetts multiple comparisons test with a single pooled variance and the Mann–Whitney test to assess differences in mean rank. CD, cluster of differentiation; i.v., intravenous; KLH, keyhole limpet haemocyanin